In summary, our findings support a model in which sustained estrogen deprivation, combined with direct GnRH-driven immunomodulation, rather than gonadotropin spillover, triggers the onset of Graves’ disease in genetically susceptible children undergoing GnRH agonist therapy. Here, GNRH1 is linked to Graves disease.